<DOC>
	<DOCNO>NCT01933412</DOCNO>
	<brief_summary>This open label clinical study design evaluate safety immunogenicity Sci-B-Vac Hepatitis B Vaccine compare Engerix-B Hepatitis B Vaccine dialysis patient . The study hypothesis vaccination Sci B Vac achieve high seroprotection rate high anti-Hepatitis B surface antibody serum titer level vaccination Engerix-B Dialysis patient categorize `` naïve '' `` previously vaccinate '' group randomize treatment . Naïve patient randomize Sci-B-Vac Hepatitis B vaccine receive vaccination three dos , 10 μg , 0 , 1 , 6 month , Engerix-B Hepatitis B vaccine give four dos , 40 μg , 0 , 1 , 2 , 6 month . Previously vaccinate patient randomize Sci-B-Vac Hepatitis B vaccine receive vaccination three dos , 20 μg , 0 , 1 , 6 month , Engerix-B Hepatitis B vaccine give four dos , 40 μg , 0 , 1 , 2 , 6 month . All vaccine administer via intra-muscular injection deltoid muscle . The study consist three period : screening period four week , 24-week open-label treatment period , 24-week safety follow-up period . The total expected duration study per subject 52 week follow : Screening period : approximately 4 week ; treatment period : 24 week ; follow period : 24 week . The primary endpoint by-vaccine difference proportion subject attain seroprotective immune response ( anti-Hepatitis B surface antibody ≥ 10 IU/mL ) 4 week last vaccination either Sci-B-Vac Engerix-B . Secondary endpoint include anti-Hepatitis B surface antibody geometric mean concentration calculate subject upon last active dose ; proportion subject anti-Hepatitis B surface antibody concentration equal 10 IU/mL subject 12 week follow first vaccine dose ; by-treatment difference serum titer level anti-Hepatitis B surface antibody 12 , 24 52 week follow first vaccination . A by-vaccine comparison adverse event also perform .</brief_summary>
	<brief_title>Efficacy Safety Hepatitis B Vaccine Chronic Kidney Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Three month dialysis treatment Chronic Kidney Disease ; antiHepatitis B surface antibody titer level &lt; 10 IU/ml antiHepatitis B surface antibody titer level &gt; 10 IU/ml Hepatitis B surface antigen positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>